$AXON

Axon (AXON) shares rose 6% to $468.42 on strong volume. The increase is attributed to optimism about higher TASER 10 sales and software adoption. The company is expected to report Q earnings of $1.94 per share, up 65.8% YoY, and revenues of $935.35M, up 31.6% YoY. The consensus EPS estimate has been revised 1.5% higher over the last 30 days. CAE (CAE), another aerospace-defense stock, rose 1.4% to $24.05, with a 3% increase in consensus EPS estimate.

Citizens reiterated a Market Outperform rating and $700 price target for Axon Enterprise (NASDAQ: AXON), citing its ALPR technology and competitive position. Axon shares are down 17% YTD but analysts expect 33% sales growth. Q2 earnings beat expectations with $1.88 EPS on $904.3M revenue, up 35% YoY. Axon plans a $1B convertible notes offering. Needham and William Blair maintained Buy/Outperform ratings.

Axon Enterprise (AXON) shares fell after announcing a $1 billion 0% convertible debt offering due in 2031. The move raises dilution concerns and highlights declining cash reserves. Despite a 30% drop from August highs, AXON reported 41% growth in future contracted bookings in Q2. Analysts maintain a 'Strong Buy' rating with a $715 price target.

Hays County Commissioners voted to reallocate $4.5 million from a potential 10-year contract with Axon, an AI public safety company. The funds will instead pay for two additional corrections officers. Axon's proposed services included AI-driven translation and report-writing tools. The Sheriff's Office currently uses Axon's body cameras.

Axon Enterprise's shares rose after it priced a $1 billion convertible notes offering. The company's stock is currently trading at 468.42 USD, with a 5-day change of +5.96%. This news comes amid a broader market decline following a Federal Reserve policy rate increase.

Axon Enterprise Inc. (AXON) stock rose 6.36% on September 16, 2026, despite a recent 25% pullback from highs. The company announced a $1B convertible note deal, causing initial sell-off. Analysts remain bullish, with an average price target of $725. AXON reported $2.78B revenue, 30% annual growth, and strong margins.

Axon Enterprise (AXON) fell as the S&P 500's biggest loser after announcing a $1 billion 0% convertible note issuance. Proceeds will support operations, acquisitions, and investments, with a hedge to limit share dilution. The stock decline exceeded implied dilution estimates.

Skyworks Solutions (SWKS) and Qorvo (QRVO) rose 10% and 7% respectively, recovering from prior sell-offs. Axon (AXON) fell 9% after a $1B convertible note sale. Revvity (RVTY) jumped 7% to a 52-week high, citing strong backlog. Dave & Buster's (PLAY) dropped 17% after missing Q2 revenue and EBITDA estimates. Enova (ENVA) tumbled 25% after withdrawing a regulatory application. Sysco (SYY) slid 3% on a 12.3M share offering. Alignment Healthcare (ALHC) fell 18% due to business headwinds. Waystar (W

Axon (AXON) stock fell 11.3% to $434.98 on September 15, nearing its 2026 low of $424.69. The drop followed a $1B convertible note offering, but analysts attribute it to a long-term valuation compression and cash position decline. Axon's forward P/E multiple has dropped from 81.07 to 54.55. Wall Street's average price target is $706.21, though targets have lagged the stock's 32% decline over the past year.

Axon Enterprise (AXON) plans to issue $1B in 0% convertible notes due 2031, with an option for $150M more. Proceeds will be used for capped call transactions and general corporate purposes. GF Value™ suggests AXON is 24.7% undervalued, with an intrinsic value of $650.74 vs. current price of $490.18. AXON's GF Score™ is 88/100, indicating strong business quality and growth potential. Insiders sold $141M in shares over the past year, with no purchases.